The Company anticipates sharing initial results from the study in March 2025. These results will inform Silexion's development strategy for SIL-204.
In a challenging year for Moringa Acquisition Corp (SLXN), the company's stock has plummeted to a 52-week low, trading at $0.79, with a market capitalization of just $1.29 million. InvestingPro ...
In a report released on January 27, Naz Rahman from Maxim Group reiterated a Buy rating on Silexion Therapeutics (SLXN – Research Report), with a price target of $9.00. The company’s shares ...
On Tuesday, Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. SIL-204, administered in an extended-release ...
Why Lattice Semiconductor Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ...
NEW YORK--(BUSINESS WIRE)--PESG Research releases new market update: Silexion Therapeutics (NASDAQ: SLXN)* continues to strengthen its position in the precision oncology landscape with ...
(RTTNews) - Silexion Therapeutics Corp. (SLXN), a clinical-stage biotechnology company, announced Tuesday significant preclinical data for SIL-204, its next-generation siRNA therapeutic candidate ...
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...